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BACKGROUND: The objective of this study was to compare cycle control, cycle-related characteristics and body-
weight effects of NuvaRing with those of a combined oral contraceptive (COC) containing 30 mg of ethinyl estradiol
and 3 mg of drospirenone. METHODS: A randomized, multicentre, open-label trial in which 983 women were
treated (intent-to-treat population) with NuvaRing or the COC for 13 cycles. RESULTS: Breakthrough bleeding or
spotting during cycles 2–13 was in general less frequent with NuvaRing than that with the COC (4.7–10.4%) and
showed a statistically significant odds ratio of 0.61 (95% confidence interval: 0.46, 0.80) with longitudinal analysis.
Intended bleeding was significantly better for all cycles with NuvaRing (55.2–68.5%) than that with the COC
(35.6–56.6%) (P < 0.01). Changes from baseline in mean bodyweight and body composition parameters were relatively
small for both groups with no notable between-group differences. CONCLUSION: NuvaRing was associated with better
cycle control than the COC, and there was no clinically relevant difference between the two groups in bodyweight.
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Introduction
Combined oral contraceptives (COCs) are a well-established
method of contraception demonstrating proven efficacy for over
40 years. More recent advances in contraception have led to the
development of lower dose COCs in an effort to reduce
unwanted side effects such as nausea and breast tenderness.
However, reducing the dose of estrogen can compromise cycle
control, which is a key factor affecting contraceptive acceptabil-
ity, compliance and convenience (Rosenberg et al., 1995, 1999).
Another factor that may affect contraceptive acceptability is
concern about bodyweight increase. Many women and physi-
cians believe that an association exists between the use of hor-
monal contraceptives and weight gain. However, the analysis
of the literature reveals either minimal weight increases or little
evidence for a causal relationship (Gupta, 2000). Furthermore,
comparative studies show no evidence of weight gain in COC
users compared with non-users over a period of 6 months
(Reubinoff et al., 1995) or 1 year (Carpenter and Neinstein,
1986). Despite the lack of conclusive evidence, user’s and phy-
sician’s concerns about weight gain remain and may affect
decisions about the choice of contraceptive method.
NuvaRing is a flexible combined hormonal contraceptive
ring that releases 15 μg of ethinyl estradiol (EE) and 120 μg of
etonogestrel per day intended for a 3-week cycle use. The main
advantage of NuvaRing is the convenience of once-a-month
administration. In addition, NuvaRing offers the use of lower
doses of contraceptive hormones (Timmer and Mulders, 2000),
and its controlled-release delivery via the vaginal route avoids
the daily fluctuations in hormone levels that can occur with
COCs. The excellent efficacy, tolerability and acceptability of
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NuvaRing have been established in large-scale studies con-
ducted in Europe and North America (Roumen et al., 2001;
Dieben et al., 2002; Oddsson et al., 2005a,b). A combined ana-
lysis of three small-scale, open-label trials showed that cycle
control was better with NuvaRing compared that with a COC
containing 30 μg of EE and 150 μg of levonorgestrel (Bjarnadottir
et al., 2002). This result was confirmed in a recent large-scale
comparative trial which demonstrated that NuvaRing produced
superior cycle control compared with that by the same COC
(Oddsson et al., 2005b). These earlier studies have also shown
that NuvaRing does not produce clinically significant changes
in bodyweight, but so far, the effect of NuvaRing on body-
weight has not been compared directly with that of a COC.
The primary aims of this study were to compare the effects
of NuvaRing with those of a COC containing 30 μg of EE and
3 mg of drospirenone on vaginal bleeding characteristics and
weight neutrality and to demonstrate the non-inferiority of
NuvaRing on bodyweight versus the COC. Secondary objec-
tives included contraceptive efficacy, acceptability, body com-
position changes and cycle-related characteristics [including
premenstrual syndrome (PMS) and dysmenorrhoea]. A com-
parison of the efficacy, acceptability and tolerability of these
two contraceptives will be discussed in a separate article.
Materials and methods
This randomized, open-label, multicentre trial was conducted in gynae-
cological and/or general practitioner’s practices in 10 European coun-
tries (Austria, Belgium, Denmark, France, Germany, Italy, Norway,
Spain, Sweden and Switzerland) between May 2002 and April 2004.
The study was approved by the independent ethics committee/institu-
tional review boards of the participating centres and was conducted in
accordance with the Declaration of Helsinki and the ICH Guideline for
Good Clinical Practice. All subjects provided written informed consent.
Subjects
Women included in this study were ≥18 years of age, at the risk of
pregnancy and seeking contraception. Exclusion criteria included the
use of an injectable hormonal contraceptive within 6 months of initia-
tion of the study; abortion or breastfeeding within 2 months before the
start of trial medication; abnormal cervical smear diagnosed during
screening; and any contraindication for contraceptive steroid use
including the presence of, history of or predisposition to venous or
arterial thrombosis.
Treatments
Subjects received treatment for 13 consecutive cycles. Each cycle com-
prised a 21-day ring/pill treatment period followed by a 7-day ring/pill-
free period. Women were randomized to the NuvaRing (NuvaRing®,
NV Organon, Oss, The Netherlands) and COC [containing 30 μg of EE
and 3 mg of drospirenone (Yasmin®, Schering AG, Berlin, Germany)]
treatment groups in randomly permuted treatment blocks (1:1 NuvaRing :
COC ratio). To ensure non-predictability of treatment allocation, we
generated blocks of 4 and 6 positions using SAS software (version
6.12). To avoid assignment bias, we carried out randomization using
an APEX (APEX Voice Communications, Woodland Hills, CA,
USA), Interactive Voice Response System. Investigators contacted the
server by telephone, entered the subject number and date of birth and
were given a medication number that corresponded to the treatment
linked to the first free block position.
Ring use and pill intake
At study entry, women received instruction on ring use, including how
and when to insert and remove it. Women taking no hormonal contra-
ception before the study inserted the ring between days 1–5 of the
menstrual cycle according to the instructions in the package insert.
Women with no hormonal contraceptive use in the past month started
pill-taking on the first day of menstrual bleeding. For both NuvaRing and
COC groups, women who had been using other methods of contracep-
tion followed the instructions in the NuvaRing or COC package inserts,
respectively, according to the method they were using.
Assessments
Assessments occurred at screening (within 1 month before starting
treatment) and within 1 week after the ring/pill-free period of cycles 1,
3, 6, 9 and 13 or at premature discontinuation.
Cycle control
Diary cards were issued at screening and used for daily documentation of
vaginal bleeding patterns up to and including the ring/pill-free period of
cycle 13. If vaginal bleeding was present, subjects indicated whether it was
considered to be spotting (requiring ≤1 pad/tampon per day) or bleeding
(requiring ≥2 pads/tampons per day). Withdrawal bleeding was classified
as any bleeding/spotting that occurred during the ring/pill-free period. Any
withdrawal bleeding starting before the ring/pill-free period and continuing
into the ring/pill-free period was termed early withdrawal bleeding. Con-
tinued withdrawal bleeding was defined as any withdrawal bleeding that
continued into the ring/pill-use period of the next cycle. Breakthrough
bleeding/spotting was defined as any bleeding/spotting episode that
occurred during the ring/pill-use period that was not early or continued
withdrawal bleeding. Intended bleeding was defined as an ‘ideal’ bleeding
pattern—i.e. a cycle without any breakthrough bleeding/spotting and in
which withdrawal bleeding only occurred during the ring/pill-free week.
PMS and dysmenorrhoea
Pretreatment PMS and dysmenorrhoea were assessed by investigators
who briefly interviewed subjects about their last menstrual period before
screening. During study assessments, subjects were also asked about the
presence and severity of PMS and dysmenorrhoea in the preceding
cycle(s). No standardized process, definitions of PMS and dysmenor-
rhoea or questionnaire was used in these assessments, and investigators
used local clinical standards and the information provided by subjects to
classify PMS and dysmenorrhoea as none, mild, moderate or severe.
Bodyweight and composition
Bodyweight measurements and body composition assessments were
performed at screening and at each study visit. To standardize body-
weight measurements, we measured weight while the subject was
wearing underwear only, and measurements were performed at the
same time of day (e.g. morning or afternoon) at each visit using a
weighing scale provided to the investigator by the sponsor.
Bodyweight measurements were used to estimate the mean weight
change from baseline within each treatment group and the difference
in weight change in the NuvaRing group compared with that the COC
group, based on the intent-to-treat (ITT) analyses.
Body composition (mass compartment, fluid compartment and
metabolism) was assessed using bio-impedance analysis (BIA) (resist-
ance and reactance). Electrodes were placed on the subject’s wrist and
ankle (both on the right side of the body). A small amount of electrical
current (300–800 μA) was passed through the subject’s body from
one electrode to the other. Between the electrode and the subject, a
resistor (500 Ω) was added to the circuit. Resistance and reactance
were recorded to determine body fat, body water and lean body mass.
I.Milsom et al.
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If the resistance value was less than the reactance value, if the resistance
value was <100 Ω, or if the values were obtained from a non-calibrated
or incorrectly calibrated BIA system, the data were not used for deri-
vation of the body composition parameters.
Statistical methods
The ITT group consisted of all randomized subjects from the all-sub-
ject-treated group—i.e. all randomized subjects who received at least
one ring/pill.
Cycle control data were analysed using descriptive statistics and tested
between groups using the two-sided Fisher exact test adjusting for coun-
try for the ITT population. The sample size was based on the assumption
that 500 randomized subjects per treatment arm would provide 350 eval-
uable ITT cycles in each of cycles 2–13 for both arms. The trial was
designed to detect a statistically significant lower incidence of break-
through bleeding/spotting episodes for the cycle 2–13 period with >80%
probability. Cycle 1 was excluded from the primary efficacy analysis to
prevent bias towards NuvaRing because of different starting procedures.
The occurrence of breakthrough bleeding/spotting was assessed for each
cycle during cycles 2–13 using two-sided testing at the 5% significance
level, corrected for multiplicity by Bonferroni’s rule. This analysis implied
overall superiority if a statistically significant lower incidence was reported
in ≥1 cycle in the NuvaRing group versus the COC group. In addition, an
explorative longitudinal analysis using the generalized estimating equations
technique with a logistic link function and a general error-covariance
matrix was applied, adjusting for country. Because of its longitudinal char-
acter, this analysis did not require an adjustment for multiplicity.
Where possible, secondary cycle control parameters (breakthrough/
withdrawal/intended bleeding) were assessed for cycles 1–13. These
parameters were analysed using the Fisher exact test adjusted for
country at a 5% significance level without adjusting for multiplicity.
Weight neutrality analysis, performed on both the NuvaRing and COC
groups, was considered to be demonstrated if the upper bound of the two-
sided 95% confidence interval (CI) based on Student’s t-distribution of the
mean change from baseline in the NuvaRing or COC group at the last
assessment in the ITT group was <1.5 kg. Weight non-inferiority was con-
sidered to be established if the difference in adjusted (for age and baseline
bodyweight) change from baseline in bodyweight at the last assessment
between the NuvaRing and the COC was <0.75 kg with 95% probability.
The calculation of this adjusted treatment contrast was performed using an
analysis of covariance (ANCOVA) with baseline bodyweight and age as
covariates and treatment as factor. The impact of possibly different discon-
tinuation rates on the primary results of last measurements was analysed
by additional analysis, restricting the attention/analysis to completers only.
Body composition parameters were derived from the reactance, resist-
ance, and bodyweight and height along the lines given by Kottler et al.
(1996) as follows: mass compartment (fat-free mass, fat mass, body cell
mass and extracellular mass), fluid compartment (total body water, intra-
cellular water and extracellular water) and metabolism (basal metabolic
rate). For each parameter, change and relative change from baseline for
the ITT group were analysed using ANCOVA with treatment and coun-
try as factors and the respective baseline value as covariate.
Results
Subject disposition
The first subject was screened in May 2002, and the final
assessment of the last subject was in April 2004. Of the 1017
randomized subjects, 34 discontinued before treatment: 7
(NuvaRing, n = 4; COC, n = 3) were pregnant at screening; 1
(COC) was lost to follow-up; 1 (NuvaRing) had no further
need for contraception; 10 (NuvaRing, n = 6; COC, n = 4) were
not willing to co-operate any further; 15 (NuvaRing, n = 6;
COC, n = 9) for other reasons (Figure 1). Of the 983 subjects
(NuvaRing, n = 499; COC, n = 484) who were randomized and
treated (ITT group), 267 [NuvaRing, n = 144 (28.9%); COC,
n = 123 (25.4%)] discontinued prematurely, primarily due to
adverse events (NuvaRing, n = 61; COC, n = 48) and other rea-
sons (NuvaRing, n = 32; COC, n = 23); 716 women completed
the trial [NuvaRing, n = 355 (71.1%); COC, n = 361 (74.6%)].
There were no notable differences between treatment groups
in baseline demographic and clinical characteristics (Table I).
Figure 1. Subject disposition. COC, combined oral contraceptive;
ITT, intent to treat.
Subjects screened 
N=1018 
Not randomised 
N=1 
Subjects randomised 
N=1017 
Randomised and not treated
N=34
Subjects randomised and 
treated (ITT group) N=983
 NuvaRing COC 
499 484 
Discontinuations: 144
Pregnancy: 1  
Unacceptable vaginal bleeding: 6 
Felt ring during intercourse: 16 
Lost to follow-up: 11
No further need for contraception: 11
Not willing to cooperate: 6
Adverse events: 61 
Other reasons: 32
Discontinuations: 123
Pregnancy: 8*
Unacceptable vaginal bleeding: 3 
Lost to follow-up: 16
No further need for contraception: 7 
Not willing to co-operate: 18
Adverse events: 48 
Other reasons: 23
355 Completed
treatment 
361 
*4 in-treatment pregnancies, 3 pre-treatment pregnancies ( ITT subjects who were
pregnant but had started treatment) and one post-treatment pregnancy (investigator indicated 
“pregnancy” as reason for discontinuation on the end of trial form) 
Table I. Baseline demographic and clinical characteristics for the NuvaRing 
and combined oral contraceptive (COC) treatment groups [intent-to-treat 
(ITT) population]
NuvaRing (n = 499) COC (n = 484)
Age, mean ± SD (years) 26.6 ± 6.1 26.6 ± 6.2
Race, n (%)
Caucasian 488 (97.8) 476 (98.3)
Weight, mean ± SD (kg) 62.4 ± 8.4 62.7 ± 8.1
Body mass index, mean ± SD (kg/m2) 22.4 ± 2.6 22.5 ± 2.6
Nulligravid, n (%) 306 (61.3) 297 (61.4)
Nulliparous, n (%) 345 (69.1) 334 (69.0)
Cycle control with NuvaRing versus oral contraceptive
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Efficacy and compliance
There was one in-treatment pregnancy in the NuvaRing group
(Pearl Index = 0.25; 95% CI: 0.006, 1.363) and four in the
COC group (Pearl Index = 0.99; 95% CI: 0.269, 2.530). Com-
pliance rates were high in both treatment groups (89.2 and
85.5% for the NuvaRing and COC groups, respectively). These
data will be described in more detail in a separate publication.
Cycle control
Breakthrough bleeding/spotting
The incidence of breakthrough bleeding/spotting during cycles
2–13 ranged from 3.6 to 6.2% in the NuvaRing group and from
4.7 to 10.4% in the COC group (Figure 2). The incidence of
breakthrough bleeding/spotting was lower with NuvaRing than
that with the COC for all cycles, except cycles 11 and 12. Sta-
tistical analysis revealed a trend towards superiority with
NuvaRing (P = 0.068), but as this did not achieve statistical
significance, superiority could not be demonstrated. This trend
towards a lower occurrence of breakthrough bleeding/spotting
was confirmed by the exploratory longitudinal analysis that
resulted in a statistically significant odds ratio of 0.61 (95% CI:
0.46, 0.80). In addition, when NuvaRing was compared with the
COC on the basis of individual cycles (i.e. without the correction
for multiplicity), there were statistically significant lower inci-
dences of breakthrough bleeding/spotting with NuvaRing in
cycles 4 (P = 0.046), 6 (P = 0.038) and 10 (P = 0.006). The mean
number of bleeding/spotting days in a single episode ranged
from 1.4 to 4.5 days over cycles 2–13 for the NuvaRing group
and from 1.8 to 3.3 days for the COC group (Table II).
The incidence of breakthrough bleeding alone ranged from
0.3 to 1.8% for the NuvaRing group and from 0.3 to 2.8% for
the COC group over cycles 1–13 (Figure 3). Fewer occur-
rences of breakthrough bleeding were observed in the
NuvaRing group during cycle 1 (P < 0.05). This statistically
significant effect was most likely due to the difference in
starting procedures.
The incidence of breakthrough spotting alone ranged from
2.6 to 8.5% for NuvaRing and from 4.4 to 16.9% for the COC
over cycles 1–13 (Figure 3). Significantly fewer breakthrough
spotting episodes were observed in the NuvaRing group during
cycles 1, 3, 4, 6 and 10 (P < 0.05).
Withdrawal bleeding
The mean number of withdrawal bleeding days ranged from
2.2 to 2.8 days for the NuvaRing group and from 2.6 to 3.0
days for the COC group (Table II). Further information on
withdrawal bleeding characteristics is presented in Table III.
The incidence of cycles (1–13) without withdrawal bleeding
ranged from 0.2 to 3.2% for NuvaRing- and from 0.5 to 1.7%
for COC-treated subjects, with no statistically significant dif-
ferences between the groups in any cycle.
Significantly more early withdrawal bleedings were
observed in the NuvaRing group compared with those in the
COC group during cycles 1, 5, 8 and 12 (P < 0.05). Between-
group differences for continued withdrawal bleeding were
statistically significant in each of cycles 1–12 in favour of
NuvaRing (P < 0.0001). In both groups, early and continued
withdrawal bleeding consisted mainly of days of spotting
Figure 2. The incidence of breakthrough bleeding and spotting dur-
ing the ring/pill period in subjects receiving NuvaRing or a combined
oral contraceptive (COC) during cycles 2–13.
Table II. Number of breakthrough bleeding/spotting days and withdrawal bleeding days [intent-to-treat (ITT) population]
COC, combined oral contraceptive.
Cycle Breakthrough bleeding/spotting days Withdrawal bleeding days
NuvaRing COC NuvaRing COC
Mean (SD) Median (range) Mean (SD) Median (range) Mean (SD) Median (range) Mean (SD) Median (range)
1 3.8 (3.8) 2.0 (1–14) 3.8 (3.0) 3.0 (1–13) 2.8 (1.8) 3.0 (0–13) 3.0 (2.0) 3.0 (0–20)
2 1.8 (1.3) 1.0 (1–7) 2.6 (1.9) 2.0 (1–7) 2.6 (1.8) 3.0 (0–19) 2.9 (2.0) 3.0 (0–28)
3 2.3 (2.0) 1.0 (1–7) 2.3 (1.7) 2.0 (1–8) 2.5 (1.6) 3.0 (0–12) 2.8 (1.5) 3.0 (0–8)
4 2.0 (1.6) 1.0 (1–6) 2.0 (1.5) 1.5 (1–8) 2.5 (1.9) 2.0 (0–18) 2.8 (1.5) 3.0 (0–8)
5 1.4 (0.8) 1.0 (1–4) 3.3 (2.6) 2.5 (1–10) 2.5 (1.7) 2.0 (0–11) 2.7 (1.5) 3.0 (0–8)
6 4.5 (4.5) 2.0 (1–15) 2.5 (1.8) 2.0 (1–7) 2.4 (1.6) 2.0 (0–12) 2.7 (1.6) 3.0 (0–10)
7 2.2 (1.5) 2.0 (1–6) 2.1 (1.5) 2.0 (1–6) 2.4 (1.5) 2.0 (0–8) 2.7 (1.5) 3.0 (0–7)
8 2.5 (2.6) 1.0 (1–11) 2.1 (1.5) 1.5 (1–7) 2.4 (1.6) 2.0 (0–8) 2.7 (1.5) 3.0 (0–7)
9 2.3 (1.4) 2.0 (1–6) 2.7 (1.6) 3.0 (1–6) 2.3 (1.5) 2.0 (0–7) 2.7 (1.6) 3.0 (0–7)
10 2.3 (1.8) 1.0 (1–7) 2.8 (2.1) 2.0 (1–8) 2.4 (1.5) 2.0 (0–7) 2.7 (1.6) 3.0 (0–8)
11 2.7 (2.4) 2.0 (1–9) 1.8 (1.0) 1.5 (1–4) 2.3 (1.6) 2.0 (0–11) 2.7 (1.5) 3.0 (0–8)
12 2.5 (1.5) 2.0 (1–5) 1.9 (1.1) 1.5 (1–4) 2.2 (1.4) 2.0 (0–6) 2.7 (1.5) 3.0 (0–7)
13 2.7 (1.9) 2.0 (1–6) 2.8 (1.9) 2.0 (1–7) 2.4 (1.8) 2.0 (0–16) 2.6 (1.4) 3.0 (0–7)
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during the ring/pill period (Table III). The mean number of
withdrawal bleeding days ranged from 2.2 to 2.8 days and from
2.6 to 3.0 days over cycles 1–13 for the NuvaRing and COC
groups, respectively.
Intended bleeding
The incidence of intended bleeding was significantly higher in
the NuvaRing group (55.2–68.5%) than that in the COC group
(35.6–56.6%) for each of the cycles 1–12 (P < 0.01) (Figure 4).
Physician reporting of PMS and dysmenorrhoea
After 1 year of treatment, the reporting of moderate or severe
PMS or dysmenorrhoea decreased in both groups with no
apparent differences between the treatments. The proportion of
subjects reporting moderate or severe PMS symptoms
decreased from 12.6 to 4.5% in the NuvaRing group and from
14.7 to 4.7% in the COC group (screening versus cycle 13).
The proportion of subjects reporting moderate or severe dys-
menorrhoea also decreased at study end compared with screen-
ing (decreasing from 17.4 to 5.9% in the NuvaRing group and
from 19 to 6.4% in the COC group).
Bodyweight
Weight neutrality
The mean bodyweight per cycle of assessment is summarized
in Table IV and was similar for NuvaRing and COC groups.
For the NuvaRing ITT group, the estimated mean bodyweight
change from baseline to the last assessment was 0.37 kg (two-
sided 95% CI: 0.10, 0.64; Table V). For the COC ITT group,
the estimated mean bodyweight change from baseline was –
0.03 kg (two-sided 95% CI: –0.29, 0.23). In both cases, the
upper limit of the two-sided 95% CI was below the pre-speci-
fied 1.5 kg; therefore, it was concluded that weight neutrality
of both the NuvaRing and the COC was demonstrated. Results
for the study completers were similar.
Weight non-inferiority
The estimated adjusted mean difference (NuvaRing – COC) in
change from baseline in bodyweight in the ITT group at the
last assessment was 0.38 kg lower in the COC group as com-
pared with the NuvaRing group. As the upper limits of the 95%
CIs of the adjusted mean differences were above the pre-speci-
fied 0.75 kg (0.76), the non-inferiority of NuvaRing versus
COC could not be demonstrated. Results of the study compl-
eters were similar.
Body composition
At the end of the trial (after cycle 13), no clear changes from
baseline in body composition were observed for both treatment
groups. The changes from baseline in all body composition
parameters were relatively small for both NuvaRing and the
COC (Tables VI and VII). Overall no clear differences were
Figure 3. The incidence of breakthrough bleeding or spotting during
the ring/pill period in subjects receiving NuvaRing or a combined oral
contraceptive (COC) during cycles 1–13.
Table III. Incidence (%) of withdrawal bleeding parameters (cycles 1–13 
unless otherwise stated)
COC, combined oral contraceptive.
Cycle control parameter NuvaRing COC
Absence of withdrawal bleeding 0.2–3.2 0.5–1.7
Early withdrawal bleeding 2.0–11.8 0.8–7.0
Early withdrawal bleeding/spotting only 0.8–8.3 0.8–4.4
Continued withdrawal bleeding (cycles 1–12) 22.9–28.5 37.7–49.1
Continued withdrawal bleeding/spotting only 
(cycles 1–12)
19.4–23.2 28.0–38.4
Figure 4. The incidence of intended bleeding in subjects receiving
NuvaRing or a combined oral contraceptive (COC) during cycles 1–12.
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Table IV. Bodyweight (mean ± SD) per assessment for NuvaRing and 
combined oral contraceptive (COC) groups [intent-to-treat (ITT) population]
Data in parentheses denote the population (n).
Assessment Bodyweight, mean ± SD
NuvaRing (n = 499) COC (n = 484)
Baseline 62.4 ± 8.4 (494) 62.8 ± 8.1 (474)
After cycle 1 62.2 ± 8.4 (462) 62.6 ± 8.0 (450)
After cycle 3 62.1 ± 8.5 (428) 62.7 ± 8.0 (430)
After cycle 6 62.4 ± 8.5 (390) 62.7 ± 8.0 (390)
After cycle 9 62.5 ± 8.5 (366) 62.9 ± 8.2 (365)
After cycle 13 62.7 ± 8.8 (301) 63.3 ± 8.5 (294)
Last assessment 62.8 ± 8.8 (477) 62.8 ± 8.2 (461)
Cycle control with NuvaRing versus oral contraceptive
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found between the treatment groups in the mass compartment
and fluid compartment parameters and metabolic rate.
Discussion
The results of this randomized multicentre, open-label, trial
demonstrate that NuvaRing produced better cycle control than
a COC containing 30 μg of EE and 3 mg of drospirenone and
that there was no clinically relevant difference in bodyweight
change between the two treatments.
Good cycle control is a key factor influencing compliance
and acceptability. Because of the vaginal route of administra-
tion, good cycle control with NuvaRing is especially important
because breakthrough or prolonged withdrawal bleeding may
Table V. Bodyweight neutrality analyses (mean ± SD) for NuvaRing and combined oral contraceptive (COC) groups [intent-to-treat (ITT) population]
aData in parentheses denote the population (n).
Analysis group Weight (kg) Estimate (95% CI)
Baseline (actual values) Last measurement (actual values) Last measurement (change from baseline)
NuvaRing 62.4 ± 8.4 (494)a 62.8 ± 8.8 (477)a 0.4 ± 3.0 (477)a 0.37 (0.10, 0.64)
COC 62.8 ± 8.1 (474)a 62.8 ± 8.2 (461)a −0.0 ± 2.8 (460)a −0.03 (−0.29, 0.23)
Table VI. Change from baseline in body mass parameters for NuvaRing and combined oral contraceptive (COC) groups [intent-to-treat (ITT) population]
*P = 0.042 versus baseline.
Parameter Visit n Mean (SD) Adjusted mean difference 
(NuvaRing – COC)
NuvaRing COC Estimate 95% CI
Fat-free mass (kg) Baseline 484 45.0 (5.4) 45.1 (5.2)
After cycle 6 381 −0.2 (3.7) −0.1 (3.4) −0.32 (−0.85, 0.22)
After cycle 13 297 −0.1 (3.6) 0.0 (4.1) −0.13 (−0.80, 0.53)
Last 467 0.0 (3.7) −0.2 (3.9) 0.15 (−0.38, 0.69)
Fat mass (kg) Baseline 484 17.4 (7.2) 17.7 (7.1)
After cycle 6 381 0.2 (4.2) −0.3 (4.0) 0.70* (0.03, 1.37)
After cycle 13 297 0.6 (4.7) 0.1 (4.6) 0.54 (−0.33, 1.42)
Last 467 0.3 (4.6) 0.1 (4.6) 0.25 (−0.44, 0.93)
Body cell mass (kg) Baseline 484 21.7 (3.7) 21.7 (3.7)
After cycle 6 381 −0.1 (3.0) 0.0 (2.8) −0.17 (−0.58, 0.25)
After cycle 13 297 0.0 (3.0) 0.2 (3.2) −0.11 (−0.64, 0.42)
Last 467 0.1 (3.0) 0.0 (3.2) 0.10 (−0.32, 0.52)
Extracellular mass (kg) Baseline 484 23.3 (2.3) 23.5 (2.2)
After cycle 6 381 −0.1 (1.7) −0.1 (1.6) −0.14 (−0.39, 0.11)
After cycle 13 297 −0.2 (1.6) −0.2 (1.5) 0.00 (−0.28, 0.28)
Last −0.0 (1.6) −0.2 (1.6) 0.04 (−0.18, 0.27)
Table VII. Change from baseline in fluid compartment parameters and basal metabolic rate for NuvaRing and combined oral contraceptive (COC) groups [intent-
to-treat (ITT) analyses]
Parameter Visit n Mean (SD) Adjusted mean difference 
(NuvaRing – COC)
NuvaRing COC Estimate 95% CI
Total body water (l) Baseline 484 34.1 (4.5) 34.2 (4.3)
After cycle 6 381 −0.2 (3.1) −0.1 (2.9) −0.22 (−0.67, 0.23)
After cycle 13 297 −0.1 (3.0) 0.0 (3.4) −0.06 (−0.62, 0.50)
Last 467 0.1 (3.1) −0.1 (3.3) 0.17 (−0.28, 0.62)
Intracellular water (l) Baseline 484 0.259 (0.034) 0.260 (0.033)
After cycle 6 381 −0.001 (0.024) −0.001 (0.022) −0.0016 (−0.0051, 0.0018)
After cycle 13 297 −0.001 (0.023) 0.000 (0.026) −0.0005 (−0.0047, 0.0038)
Last 467 0.000 (0.023) −0.001 (0.025) 0.0013 (−0.0021, 0.0047)
Extracellular water (l) Baseline 484 33.9 (4.5) 34.0 (4.3)
After cycle 6 381 −0.2 (3.1) −0.1 (2.8) −0.21 (−0.66, 0.23)
After cycle 13 297 −0.1 (3.0) 0.0 (3.4) −0.06 (−0.61, 0.49)
Last 467 0.1 (3.0) −0.1 (3.3) 0.17 (−0.27, 0.62)
Basal metabolic rate (kCal) Baseline 484 1469.2 (239.8) 1464.9 (233.6)
After cycle 6 381 −9.4 (216.1) 1.3 (194.4) −10.14 (−39.09, 18.81)
After cycle 13 297 0.9 (213.1) 14.0 (224.9) −2.83 (−39.28, 33.62)
Last 467 5.1 (211.3) 0.2 (221.2) 8.85 (−20.00, 37.71)
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particularly be of inconvenience to the user. With a low daily
dose of 15 μg EE, NuvaRing has consistently been shown to
have excellent cycle control in several large studies (Roumen
et al., 2001; Bjarnadottir et al., 2002; Dieben et al., 2002;
Oddsson et al., 2005b). Furthermore, cycle control with
NuvaRing has been shown to be superior to that with a COC
containing 30 μg of EE and 150 μg of levonorgestrel (Bjarnadottir
et al., 2002; Oddsson et al., 2005b). In the present study,
NuvaRing once again displayed cycle control characteristics
that were better than those of the COC in almost all aspects.
The incidence of breakthrough bleeding/spotting in cycles
2–13 was lower in the NuvaRing group than that in the COC
group in the majority of cycles. This difference approached
statistical significance in the per-cycle analysis and was statis-
tically significant in the more appropriate longitudinal analysis.
The discrepancy between the two analyses may come from the
fact that the longitudinal analysis uses the within-subject corre-
lation between the different cycles to provide more precise
estimates. This may lead to more power than in the per-cycle
analysis where the Bonferroni adjustment for multiplicity does
not take these correlations into account. The incidence of
intended bleeding patterns, which provides an overall measure
of several cycle control parameters, was significantly higher
with NuvaRing than that with the COC throughout cycles 1–12
and provides evidence that cycle control was better with
NuvaRing than that with the COC. The low incidence of break-
through bleeding/spotting in cycles 2–13 with NuvaRing was
similar to that previously reported [e.g. 2.6–6.4% of cycles 1–13
(Roumen et al., 2001) and 2.0–6.4% of cycles 2–13 (Oddsson
et al., 2005b)]. In addition, the majority of this bleeding was
restricted to spotting, with an incidence of breakthrough bleed-
ing of ≤1.8%. The low incidence of breakthrough bleeding
with NuvaRing may be explained by NuvaRing’s continuous
release of contraceptive hormones, which is in contrast to the
situation with COCs, in which circulating concentrations of
contraceptive hormones fluctuate daily. The incidence of irreg-
ular bleeding/spotting with the COC in cycles 2–13 in our
study (4.7–10.4%) was also similar to that reported with
another COC containing 30 μg of EE and 150 μg of levonorg-
estrel (range 3.5–12.6%) in a previous comparison with
NuvaRing (Oddsson et al., 2005b).
Withdrawal bleeding is generally considered a desirable
feature, as it helps reassure women of the absence of preg-
nancy. In the present study, almost all women in both treat-
ment groups had withdrawal bleeding. Early withdrawal
bleeding (mainly spotting) was slightly more frequent with
NuvaRing than with the COC (incidence 2–11.8% versus
0.8–7.0%). Bleeding problems including heavy or extended
withdrawal bleeding can contribute to poor compliance
(Rosenberg et al., 1995). In our study, continued withdrawal
bleeding was significantly less frequent with NuvaRing than
that with the COC in cycles 1–12. This confirms previous
reports of a lower incidence of continued withdrawal bleed-
ing with NuvaRing compared with that with a COC (Oddsson
et al., 2005b). The results are reassuring because ring inser-
tion during continued withdrawal bleeding may be a nuisance
for some women, although this bleeding was comprised
mainly of spotting.
PMS and dysmenorrhoea are common cycle-related disor-
ders of menstruating women (Jamieson and Steege, 1996;
Dickerson et al., 2003), and in a small proportion of women,
symptoms can be disabling or incapacitating (Dickerson et al.,
2003) or associated with significant distress and life disruption
(Durain, 2004). Oral contraceptives are widely prescribed for
the management of PMS, although they have not been shown
to be consistently effective (Dickerson et al., 2003). There is
some evidence of the beneficial effects of oral contraceptives
in dysmenorrhoea (French, 2005), although a systematic
review found insufficient evidence to draw conclusions about
their effectiveness in treating this condition (Proctor et al.,
2001). In our study, the proportions of women with PMS and
dysmenorrhoea decreased in both groups, and there were also
reductions in the proportions of women with moderate or
severe PMS or dysmenorrhoea. The respective proportions of
women with PMS in the NuvaRing and COC groups at screen-
ing were 34.5 and 38.8%, but at cycle 13, these values had
decreased to 20.6 and 22.4%, respectively. The proportions
with moderate or severe PMS at screening in the NuvaRing
and COC groups were 12.6 and 14.7%, respectively, and after
cycle 13, this had decreased to 4.5 and 4.7%, respectively. The
respective proportions of women in the NuvaRing and COC
groups with dysmenorrhoea at screening were 41.7 and 42.4%,
and by cycle 13, these proportions had fallen to 21.7 and
23.0%, respectively. The proportions with moderate or severe
dysmenorrhoea at screening were 17.4 and 19.0%, respec-
tively, and these proportions had fallen to 5.9 and 6.4%,
respectively, by cycle 13.
In the present study, both contraceptives achieved weight
neutrality, but the non-inferiority of NuvaRing versus the COC
for change in bodyweight could not be demonstrated. To have
sufficient power to detect a non-inferior change in bodyweight
at the last assessment, we required 500 subjects per group.
However, fewer than 500 subjects (477 in NuvaRing and 460
in COC group) in each group had a change from baseline
assessment. This is consistent with the upper limit of the 95%
CI being just above 0.75 kg and may have resulted in or con-
tributed to the failure to demonstrate the non-inferiority of
NuvaRing.
In the NuvaRing group, the observed mean change in body-
weight of +0.37 kg was similar to that previously reported
(+0.43 kg) in a large (n = 1145 women) European 1-year effi-
cacy trial of NuvaRing (Roumen et al., 2001). The current data
are also comparable with a report that combined the European
data with those from a North American study and reported an
increase of 0.84 kg over 1 year (Dieben et al., 2002). In addi-
tion, a slight decrease in bodyweight has also been reported
with NuvaRing (–0.13 kg) over a shorter duration of use
(6 cycles) (Bjarnadottir et al., 2002). With the COC, there was
a slight decrease (–0.03 kg) in bodyweight after 13 cycles. This
decrease is less than the weight loss reported in earlier trials
with this COC over the same treatment period (–0.46 kg over a
13-cycle treatment period; Huber et al., 2000) or shorter (–0.78 kg
over 6 cycles; Oelkers et al., 1995) time frames. In contrast,
another study demonstrated a slight increase in bodyweight
using the same COC over 26 cycles, although bodyweight was
below baseline for the majority of the study (Foidart et al.,
Cycle control with NuvaRing versus oral contraceptive
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2000). Thus, it appears that the precise role of NuvaRing or
COCs in bodyweight changes in women still has to be defined.
One of the strengths of this trial is that bodyweight was eval-
uated as a primary outcome using rigorous methods for assess-
ing weight over a study duration of 1 year. Weight gain can
occur as a result of increases in a combination of factors,
including fat deposition, fluid retention or muscle mass. In this
trial, changes in all body composition parameters, including fat
and fat-free mass, body cell and extracellular mass, and total
body water were relatively small for both groups with no obvi-
ous differences between treatments. This lack of difference is
interesting because drospirenone exerts an antimineralocorti-
coid effect on the renin-angiotensin-aldosterone system
(Foidart, 2000), which is said to oppose the increase in water
retention caused by estrogen (Keam and Wagstaff, 2003).
Because other synthetic progestogens lack this antimineraloco-
rticoid activity, the drospirenone-containing COC used in the
present study is believed to offer an advantage over COCs due
to reduced water retention (Parsey and Pong, 2000). However,
in the present study, the absence of any significant difference
between the COC and NuvaRing groups in water retention was
notable. This may suggest that EE-related fluid retention can
be avoided by using a contraceptive with a low EE dose
(15 μg) such as NuvaRing; alternatively, these results may
indicate that the antimineralocorticoid effect of drospirenone is
not notable when administrated in the dose used for contracep-
tive purposes.
In conclusion, NuvaRing was associated with reduced irreg-
ular bleeding and improved cycle control and did not show
clinically relevant weight changes compared with a COC con-
taining 30 μg of EE and 3 mg of drospirenone.
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